Search 

CitareTx founded in 2008 is a venture development and investment firm based in Houston Texas. The firm provides investment and incubation services to start-up and early-stage medical device companies. The firm provides seed capital (equity) ranging from $5K to $2M with follow-on capital of up to $5M. The firm also considers investment opportunities with smaller than typically accepted venture capital market size thresholds. The firm is geographically agnostic but prefers companies to be based in Texas. The firm is actively seeking new opportunities.

Clayton Biotechnologies commercializes technologies that are developed and owned by the Clayton Foundation for Research and its supporting entities through research programs at leading research hospitals and institutions in the US and Switzerland.

We have several projects in various stages of development from discovery to advanced pre-clinical that are available for licensing, collaboration, and the creation of new start-up ventures.

Clayton Biotechnologies has a significant portfolio of technologies to offer for licensing and collaboration. 

Some of our featured technologies:

- Urocortins and analogues for Diabetes

- Fc engineering of aglycosylated antibodies

- Granzyme B - a potent payload for antibody drug conjugates (ADC)

- Alk4-Fc, a Cripto antagonist for Cancer

- TEAD gene and peptide therapies for ocular neovascular disease

- Stem cell therapy program for Parkinson's Disease

- Vaccines and Diagnostics for Ehrlichioses

- Biomarker for personalized breast cancer therapy

- YESS - engineering of proteases

- OCT Image Guided Smart Laser Knife Diagnosis and Therapy in Small Spaces

To date, 9 products based on Clayton Foundation discoveries have been have been successfully commercialized through the creation of start-up companies and out-licensing

Correlation Ventures is a venture capital firm that founded in 2010 and is based in San Diego, California with an additional office in Palo Alto, California. The firm currently has approximately $165 million in total assets under management. The firm typically makes investments ranging from $0.25 million to $5 million over the life of the company, and the first investment will be not larger than $2.5 million. The firm’s preferred capital structure is convertible preferred equity or convertible loan. Correlation Ventures will consider invest in any industry segment at any stage, but there must be at least one other venture capital firm making their first investment in the company in this round. The firm only invests in US-based companies. 

Correlation is extremely opportunistic when it comes to investments in the life sciences space; with that being said the firm's specified sectors and sub sectors of interest may or may not be an area in which Correlation Ventures is currently looking to allocate capital to. The firm has made a number of investments in companies in the life sciences space, and has mainly invested in companies in the biotech therapeutics and diagnostics space. The firm's current portfolio includes biotech therapeutics and diagnostics firms developing products targeting endocrine, metabolic, and nutritional diseases, musculoskeletal system and connective tissue, neoplasms, cancer, and oncology, genitourinary system, and infectious and parasitic diseases.

We are a Hong Kong-based venture fund management company focusing on mid- to long-term advanced technology investments at early stage. Through our partnership with the top analytical companies utilizing machine learning and large panel of experts, we can construct complex decision trees showing risk and return at every stage of company evolution. We routinely invest in both private and public companies specializing in biotechnology, drug discovery, personalized medicine, Big Data analysis, industrial expert systems and artificial intelligence. 

DELSIA is a "venture philanthropy" investment affilate of the research and advocacy foundation Autism Speaks. Our purpose is to transform lives by catalyzing the development and availability of innovative products.

DELSIA is a non-dilutive funding vehicle with the goal of improving outcomes for individuals with autism spectrum disorder (ASD). DELSIA aims to do this by enabling the translation of scientific breakthroughs and technological advances into products that improve health and quality of life for individuals with ASD and their families. 

Who and what do we invest in? DELSIA partners with for-profit companies to fund development activities necessary for delivering products that address the diverse unmet medical, behavioral health and quality of life needs of the autism community.

DELSIA accepts funding proposals from for-profit entities that include, but are not limited to:

• Entrepreneurs, start-up and small companies

• Life sciences, biotechnology and pharmaceutical companies

• Software, computer and electronic technology companies

Diamond BioFund is an evergreen fund that was established in 2013 and is based in Taipei City, Taiwan. The fund is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in Taiwan-based businesses and co-invest in businesses overseas. The fund is currently seeking new opportunities in Taiwan, Greater China, Southeast Asia, US, Canada, and EU.

Diamond BioFund takes a generalist approach when considering life science opportunities, including therapeutics (small molecule and biologics), medical devices, diagnostics, healthcare services, and nutraceuticals. The fund is seeking cutting edge, innovative, and platform technology. In therapeutics, the fund considers all stages from preclinical through pre-IPO. In medical devices, the fund prefers later stage projects with proof of concept. The fund is open to all disease indications.

Easton Capital Investment Group is a venture capital firm based in New York. Easton Capital invests broadly in the life science sector, and considers investment opportunities globally. The firm is likely to make 4-6 allocations in the next 6 months. Allocations typically vary from $250,000 to $5 million, in the form of equity or convertible debt. Allocations are typically made at the venture stage of development, but may be made in seed rounds if a company already has proof of their product's efficacy.

EIP Pharma, LLC is a private company based in Cambridge, MA.  The company has licensed-in and is developing a phase 2 clinical-stage oral small molecule that targets neuroinflammation and dysfunction of microglia, the major immune-cell in the brain.

Human genetic and other biologic data strongly indicate inflammation & microglial dysfunction are one of the major drivers of late-onset Alzheimer’s disease (AD), and likely the major driver in patients with symptomatic disease.

VX-745 (the licensed compound) specifically inhibits intra-cellular enzyme p38 mitogen activated protein kinase alpha (MAPKa).  In the brain, p38 MAPKa is a major regulator of inflammation through effects on microglia. P38 MAPKa is also expressed in neurons, where it is directly involved in memory formation and synaptic plasticity. 

VX-745 readily enters the brain, with brain concentrations in pre-clinical studies being approximately two-fold higher than in peripheral blood.  VX-745 had previously been clinically evaluated in non-CNS disorders, where already has demonstrated anti-inflammatory activity in patients. The combination of blood-brain-barrier penetration and previous clinical experience with demonstrated anti-inflammatory activity uniquely positions VX-745 to target inflammation to treat Alzheimer’s and other CNS disorders in which inflammation plays a role.

EIP Pharma licensed VX-745 from the originator company, Vertex Pharmaceuticals, and conducted animal studies to re-position the compound towards disease of the brain, including AD.  Vertex had previously completed a full chronic toxicology program and had demonstrated significant clinical and anti-inflammatory activity in a phase 2a 12-week treatment study of VX-745 in rheumatoid arthritis (RA).  An Investigational New Drug (IND) application remains open at FDA.

The animal studies conducted by EIP Pharma have demonstrated pro-cognitive effects, anti-inflammatory and other pharmacologic effects of VX-745 in the brain.  These data combined with dose response data in prior animal and clinical studies, have been utilized to identify doses that are highly likely to have positive activity in human brain.  The predicted doses are 2- to 5- fold lower than the dose that demonstrated anti-inflammatory activity and was well tolerated in RA, consistent with VX-745 preferentially distributing to the brain in animals.  Importantly, these dose levels should minimize risks of systemic toxicity that otherwise have hampered development of p38 MAPK inhibitors for peripheral disorders.  The animal studies have also generated new intellectual property (IP), including issuance of a US patent on 15 April 2014 (#8,697,627) for the use of VX-745 to lower brain amyloid plaque load.  This IP, along with additional IP that has been filed will support commercially the development of VX-745 beyond the primary composition of matter patent expiring in 2017.

Start-up activities (IRB submissions, CRO contracting, etc.) are underway for two phase 2a clinical studies in patients with AD; both studies are anticipated to be underway in early 2015.  Combined, the studies are designed to demonstrate anti-inflammatory and microglial modulatory activity in the brain.  Once demonstrated, VX-745 should have ability to demonstrate clinical proof-of-concept in AD and/or other disease indications in which neuroinflammation plays a role in disease pathogenesis.

Company was founded and is led by experienced biotech/pharma R&D executive (John Alam; former head of Alzheimer’s R&D at Sanofi, ex-Chief Medical Officer at Vertex Pharmaceuticals, led clinical development of AvonexÒ for Multiple Sclerosis) with extensive translational and drug development experience & expertise in both inflammation and CNS disorders.